Evaluate the Performance of Genetic Amplification by Polymerase Chain Reaction (PCR) and the "Mannan Antigenemia and Antimannan Antibodies Couple as a Means of Diagnosis and a Marker of Follow-up in Invasive Candidiasis.
NCT ID: NCT02333448
Last Updated: 2024-02-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
80 participants
OBSERVATIONAL
2015-06-12
2019-09-17
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
These samples will be transferred to a specialized unit and stored for a maximum of three years for use at the end of the study.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Candida PCR Diagnosis Strategy in Patients From Intensive Care Units
NCT04874441
Anidulafungin Candidemia/Invasive Candidiasis Intensive Care Study
NCT00689338
Identification of Serum and/or Plasma Biomarkers for the Diagnosis Prognosis and/or Prediction of Invasive Mycosis in Neutropenic Patients
NCT01907477
Antigenic and Antibody Detection of Candida
NCT03766932
Early Discontinuation of Empirical Antifungal Therapy and Biomarkers
NCT03538912
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
patients with suspected invasive candidiasis
Blood sample taken on the day the treatment is initiated
Blood sample taken on day 3 after initiation of treatment
Blood sample taken on day 5 after initiation of
Blood sample taken on day 7 after initiation of treatment
Blood sample taken on day 10 after initiation of treatment
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Blood sample taken on the day the treatment is initiated
Blood sample taken on day 3 after initiation of treatment
Blood sample taken on day 5 after initiation of
Blood sample taken on day 7 after initiation of treatment
Blood sample taken on day 10 after initiation of treatment
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients aged at least 18 years admitted to a medical Intensive Care or general intensive care
* Patients with suspected invasive candidiasis - that is to say:
* Presenting persistent sepsis despite broad-spectrum antibiotherapy for at least 48 hours or targeted antibiotherapy for a documented bacterial infection (sepsis will be defined according to:
* the usual SIRS criteria, at least 2 of the following 4: temperature \> 38°C or \< 36°C, tachycardia \> 90/min, respiratory rate \> 20/min or blood pressure carbon dioxide (PaCO2 ) \< 32 mmHg, leukocytosis \> 12000/mm3 or \< 4000/mm3 or \> 10% of immature forms.
* Persistent hemodynamic instability (impossibility to significantly diminish catecholamine requirement, need for rapid vascular resuscitation \> 1000 ml over the previous 24 hours)
* Candida score ≥ 3 with multifocal colonization
* Decision to initiate echinocandin therapy made by the clinician in charge of the patient
Exclusion Criteria
* Patients not covered by national health insurance
* Pregnant or breast-feeding women
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Universitaire Dijon
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU de DIJON
Dijon, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Charles MSD 2014
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.